Surrozen, Inc.
SRZNSurrozen is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway to promote tissue repair and regeneration.
Earnings
Next report
Nov 6, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Surrozen is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway to promote tissue repair and regeneration. The company leverages its proprietary SWAP and SWEETS platforms to design tissue-specific mimetics that overcome historical challenges in Wnt biology, such as manufacturability and selectivity. Its primary strategic focus is on treating serious ophthalmic diseases, including retinal vascular disorders, by restoring tissue structure and function.
Surrozen is a pioneer in selective Wnt pathway modulation, utilizing proprietary antibody engineering to create soluble, manufacturable Wnt mimetics that target specific Frizzled receptors.
FAQ
- What is Surrozen, Inc.'s market cap?
- Surrozen, Inc. (SRZN) has a market capitalization of $199.0M and trades on NASDAQ.
- Who are Surrozen, Inc.'s competitors?
- Surrozen, Inc.'s key competitors include Regeneron Pharmaceuticals, Merck & Co., AbbVie, and others. These companies compete in similar markets and product categories.
- Who does Surrozen, Inc. partner with?
- Surrozen, Inc.'s notable partners include Boehringer Ingelheim, Stanford University, TCGFB, Inc., and others.
- Where is Surrozen, Inc. headquartered?
- Surrozen, Inc. is headquartered in United States of America and employs approximately 42 people. It has been publicly traded since 2021.